Arcus Biosciences, Inc. (RCUS)
29.21
-1.38
(-4.51%)
USD |
NYSE |
Aug 28, 16:00
29.18
-0.03
(-0.10%)
After-Hours: 20:00
Arcus Biosciences Enterprise Value : 3.122B for Aug. 28, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 28, 2026 | 3.122B |
| August 27, 2026 | 3.297B |
| August 26, 2026 | 3.319B |
| August 25, 2026 | 3.421B |
| August 24, 2026 | 3.237B |
| August 21, 2026 | 3.265B |
| August 20, 2026 | 3.161B |
| August 19, 2026 | 3.266B |
| August 18, 2026 | 3.160B |
| August 17, 2026 | 3.166B |
| August 14, 2026 | 3.156B |
| August 13, 2026 | 3.077B |
| August 12, 2026 | 3.090B |
| August 11, 2026 | 3.062B |
| August 10, 2026 | 3.059B |
| August 07, 2026 | 3.047B |
| August 06, 2026 | 3.010B |
| August 05, 2026 | 2.930B |
| August 04, 2026 | 3.070B |
| August 03, 2026 | 2.920B |
| July 31, 2026 | 2.992B |
| July 30, 2026 | 3.000B |
| July 29, 2026 | 2.771B |
| July 28, 2026 | 2.847B |
| July 27, 2026 | 2.948B |
| Date | Value |
|---|---|
| July 24, 2026 | 3.021B |
| July 23, 2026 | 3.188B |
| July 22, 2026 | 3.218B |
| July 21, 2026 | 3.156B |
| July 20, 2026 | 2.990B |
| July 17, 2026 | 2.888B |
| July 16, 2026 | 2.795B |
| July 15, 2026 | 2.971B |
| July 14, 2026 | 3.010B |
| July 13, 2026 | 2.977B |
| July 10, 2026 | 3.085B |
| July 09, 2026 | 3.217B |
| July 08, 2026 | 3.255B |
| July 07, 2026 | 3.254B |
| July 06, 2026 | 3.219B |
| July 02, 2026 | 3.264B |
| July 01, 2026 | 3.085B |
| June 30, 2026 | 3.327B |
| June 29, 2026 | 3.192B |
| June 26, 2026 | 3.182B |
| June 25, 2026 | 3.087B |
| June 24, 2026 | 2.905B |
| June 23, 2026 | 2.828B |
| June 22, 2026 | 2.708B |
| June 18, 2026 | 2.342B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Halozyme Therapeutics, Inc. | 13.93B |
| AVITA Medical, Inc. | 357.44M |
| Iovance Biotherapeutics, Inc. | 3.377B |
| Editas Medicine, Inc. | 344.76M |
| Recursion Pharmaceuticals, Inc. | 1.300B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -91.00M |
| Revenue (Quarterly) | 41.00M |
| Total Expenses (Quarterly) | 132.00M |
| EPS Diluted (Quarterly) | -0.7216 |
| Gross Profit Margin (Quarterly) | 95.12% |
| Profit Margin (Quarterly) | -222.0% |
| Earnings Yield | -13.37% |
| Normalized Earnings Yield | -13.37 |